Newly diagnosed multiple myeloma: index individual patient data (survival)

Individual patient data for the index arm (McCarthy 2012, lenalidomide), the survival (progression-free survival) ML-UMR worked example; pair with ndmm_agd and ndmm_agd_covs.

Usage

ndmm_ipd

Format

A data frame with 231 rows and 9 columns:

study, treatment

study and treatment labels

subject

row identifier

age, iss_stage3, response_cr_vgpr, male

patient covariates

eventtime, status

progression-free survival time and event indicator (1 = event, 0 = censored)

Source

The McCarthy-2012 lenalidomide arm of multinma::ndmm_ipd (GPL-3; Phillippo, multinma, 2024), subset to the columns used in the survival vignette. multinma provides simulated IPD resembling published newly-diagnosed-multiple-myeloma trials; the vignette compares lenalidomide (McCarthy et al. 2012) with thalidomide (Morgan et al. 2012). See data-raw/prepare_multinma_subsets.R.

Details

The two source trials are not genuinely disconnected: McCarthy 2012 and Morgan 2012 both include a placebo arm. Those arms are omitted here deliberately, so that this pair of datasets poses the unanchored problem ML-UMR exists for. vignette("survival-outcomes") puts them back at the end to check the unanchored estimate against the anchored one.

McCarthy 2012 is the index arm because population overlap, not sample size, governs how far an unanchored comparison has to extrapolate. Unanchored MAIC effective sample size against the Morgan 2012 thalidomide arm is 35.8 of 231 (15.5\ lenalidomide arm, the other candidate for this comparison. See data-raw/prepare_multinma_subsets.R for the full pair ranking.